WallStSmart

Merck & Company Inc (MRK)vsStereotaxis Inc (STXS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 221295% more annual revenue ($66.57B vs $30.07M). MRK leads profitability with a 4.8% profit margin vs -74.2%. STXS appears more attractively valued with a PEG of 1.31. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

STXS

Avoid

24

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 7.0Quality: 5.5
Piotroski: 4/9Altman Z: -15.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued
STXSUndervalued (+33.0%)

Margin of Safety

+33.0%

Fair Value

$3.03

Current Price

$1.29

$1.74 discount

UndervaluedFair: $3.03Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

STXS1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.309/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

STXS4 concerns · Avg: 3.3/10
Price/BookValuation
9.9x4/10

Trading at 9.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$139.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-156.1%2/10

ROE of -156.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : STXS

The strongest argument for STXS centers on Debt/Equity. PEG of 1.31 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : STXS

The primary concerns for STXS are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

MRK profiles as a value stock while STXS is a turnaround play — different risk/reward profiles.

STXS carries more volatility with a beta of 1.40 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 24/100). STXS offers better value entry with a 33.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Stereotaxis Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (MRI) systems for use in the hospital's interventional operating room to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. The company is headquartered in St. Louis, Missouri.

Want to dig deeper into these stocks?